In , Anlon Healthcare Ltd (Chemicals - Speciality) is outperforming Nifty 500 with +13.0% relative strength. Fundamentals: Average.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Apr 19, 2026
What: FY27 Order Book: ₹180-190 Cr (Anlon) + ₹125-130 Cr (Apiqo)
“But our order book in existing plant is almost, for next year, around 180, 190 CR. For Apiqo, we have the order book confirmed for 125 to 130 CR.”
What: Capacity Utilisation: 90%+
“in our existing facility we are almost utilizing more than 90 percent. You can say, like, it is completely utilized right now.”
What: Export Revenue %: 60% Target
Impact: 15-17% margin differential
“we are confident to make the at least 60% of export revenue for next financial year.”
What: 9M FY26 EBITDA Margin at 26.84%
“EBITDA rose to 32.56 crore, with margins improving to 26.84 percent... demonstrating strong scale-up in operations.”
What: ₹170-180 Cr → ₹190-200 Cr
“So consolidated, it would be somewhere around INR 190 to 200 Cr.”
Earnings deceleration risks from management commentary
Trigger: Strategic shift toward regulated markets and direct exports.
Management view: Not explicitly detailed on call.
Monitor: fx
Trigger: New guidelines requiring physical audits for API manufacturers.
Impact: PAT impact: 4-month shutdown in FY24
Management view: Facility modifications completed; zero observations in recent Anvisa audit.
Monitor: regulatory
Key quotes from recent conference calls
“I think this year we are expecting somewhere around 170 to 180 CR from the existing facility at the peak. [Previous Revenue FY26 guidance]”
“So Apico Organics, what we have procured right now... we have the confirmed order book of at least 120 to 130 CR for next year. [Initiative: Acquisition of Apiqo and Bizotic]”
“launching of, around, 7 new APIs in FY 27 across additional therapeutic categories, diversifying into industrial and fine chemicals. [Initiative: Launch of 7 new APIs]”
“we are confident to make the at least 60% of export revenue for next financial year. [Risk (fx): MEDIUM]”
Headline numbers from the latest earnings call
Revenue
₹35.78 Cr
Why: Growth was driven by higher API and intermediate volumes compared to the previous year's corresponding quarter.
Revenue saw a massive YoY jump but declined sequentially due to seasonal holiday shutdowns for overseas customers.
EBITDA
₹12.54 Cr
Why: Margins were supported by operating leverage and an improved product mix favoring high-purity intermediates.
EBITDA margins remained high at 35% despite sequential revenue volatility.
PAT
₹5.15 Cr
Why: The turnaround from a loss last year was driven by scale-up in operations and continued demand across core portfolios.
The company achieved a significant turnaround from a loss in Q3 FY25 to a profit of ₹5.15 Cr.
Other Highlights
• 9M FY26 total income reached ₹121.32 crore compared to ₹71.49 crore in 9M FY25.
• 9M FY26 PAT grew significantly to ₹18.02 crore from ₹6.36 crore in H1 FY26.
• Export revenue share is expected to close at 30% for the full financial year.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
DMF Filings
21
Why: Stable pipeline awaiting commercialization.
Capacity Utilisation
90%+
Why: Increased demand for core API and intermediate portfolio.
Export Revenue Share
5%
Why: Currently low due to use of merchant exporters; direct exports to ramp up next year.
Top 5 Customer Concentration
78%
Why: High concentration due to large volumes supplied to global innovators like Menarini.
Working Capital Days
290 days
Why: High due to payment issues with a distributor; expected to drop to 180-185 days by year-end.
CDMO Molecules in Development
3
Why: One molecule validation quantity already dispatched.
Consolidated Installed Capacity
1400-1600 MTPA
Why: Massive jump due to acquisitions of Apiqo and Bizotic.
API vs Intermediate Revenue Mix
70% API / 27.2% Intermediate
Why: H1 FY26 mix; intermediates expected to rise due to backward integration sales.
Forward-looking targets from management for FY27
OPM Guidance
30–33%
Capex Plan
₹120 Cr
₹370 to ₹380 Cr
REAFFIRMED
₹100 to ₹120 Cr
Organic expansion greenfield project at the existing campus.
REAFFIRMED
Guidance Changes
FY26 Revenue: ₹170-180 Cr → ₹190-200 Cr
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +280% | +28% | Inflection Up |
| PAT (Net Profit) | +307% | +80% | Inflection Up |
| OPM | 34.7% | +2851 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 19, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Anlon Healthcare Ltd's latest quarterly results (Dec 2025) show
Anlon Healthcare Ltd's profit is growing with an turning around (inflection up) trend.
Anlon Healthcare Ltd's revenue growth trend is turning around (inflection up).
Anlon Healthcare Ltd's operating margin is volatile.
Anlon Healthcare Ltd's long-term compounding rates
Anlon Healthcare Ltd's earnings growth is turning around (inflection up) with mixed signals on a sequential basis.
Anlon Healthcare Ltd appears significantly undervalued based on our fair value analysis.
Anlon Healthcare Ltd's current PE ratio is 26.6x.
Anlon Healthcare Ltd's current PE is 26.6x.
Anlon Healthcare Ltd's price-to-book ratio is 3.5x.
Anlon Healthcare Ltd is rated Average with a fundamental score of 58/100. This score is calculated from objective financial metrics
Anlon Healthcare Ltd has a debt-to-equity ratio of N/A.
Anlon Healthcare Ltd's return ratios over recent years
Anlon Healthcare Ltd's operating cash flow is negative (FY2025).
Anlon Healthcare Ltd currently does not pay a significant dividend (yield 0.00%).
Anlon Healthcare Ltd's shareholding pattern (Mar 2026)
Anlon Healthcare Ltd's promoter holding has remained stable recently.
Anlon Healthcare Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Anlon Healthcare Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Anlon Healthcare Ltd has 5 key growth catalysts identified from recent earnings analysis
Anlon Healthcare Ltd has 2 key risks worth monitoring
In Q3 FY26, Anlon Healthcare Ltd's management highlighted
Anlon Healthcare Ltd's management has provided the following forward guidance for FY27
Anlon Healthcare Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Anlon Healthcare Ltd may be worth studying
Anlon Healthcare Ltd investment thesis summary:
Anlon Healthcare Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
